Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.

American Society of Hematology (ASH) Key Takeaways

ASH LOGOEarlier this month the MMRF attended the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In last month’s newsletter, Blake Morrison, PharmD MMRF Vice President of Medical and Scientific Affairs shared with the CoMMunity the importance of the ASH Annual conference. During ASH the MMRF shared daily key takeaways in the MMRF CoMMunity Gateway.

Day One Key Takeaways
• New oral proteasome inhibitor Ninlaro (ixazomib) studied in newly diagnosed patient in all oral combination shows promise
• Newly FDA approved antibodies Empliciti (elotuzumab) and Darzalex (daratumumab) continue to show impressive benefit for patients who have had at least one therapy (E) to those who have failed most available options (D)
• Kyprolis (carfilzomib) continuing to show strong activity in elderly and high-risk groups and potential for less frequent/more patient friendly administration

Day Two Key Takeaways
• Techniques to assess minimal residual disease (MRD) advancing
• Treatments approved for other cancers are showing promise in early studies for MM

Day Three Key Takeaways
• Checkpoint inhibitors showing real promise in treating MM
• Data continue to emerge on latest FDA therapies, showing potential in a number of patient populations and in various combinations
• New data confirm Kyprolis can effectively treat high-risk patients
• The MM pipeline remains robust with new agents like selinexor and ACY-1215 progressing in clinical trials
• Early promising experience of a novel CAR-T cell therapy

MMRF logoThe MMRF is sponsoring a webinar with details about these takeaways at 1 PM Eastern on January 13th. Drs. David Avigan and Sagar Lonial will be answering questions. Here’s a link if you’d like to register:

http://support.themmrf.org/site/R?i=Rg33WFFca4NWdAAUFQQCqQ

Feel good and keep smiling! Pat